Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2013 Apr;24(4):1044-8. doi: 10.1093/annonc/mds542. Epub 2012 Nov 7.

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.

Author information

1
Departments of Medicine (Oncology), Stanford University Medical Center, 875 Blake Wilbur Drive, CC-2338, Stanford, CA 94305, USA. radvani@stanford.edu

Abstract

INTRODUCTION:

To assess the efficacy of an abbreviated Stanford V regimen in patients with early-stage Hodgkin lymphoma (HL). PATIENTS AND METHODS PATIENTS: with untreated nonbulky stage I-IIA supradiaphragmatic HL were eligible for the G4 study. Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated.

RESULTS:

All 87 enrolled patients completed the abbreviated regimen. At a median follow-up of 10 years, FFP, DSS and OS are 94%, 99% and 94%, respectively. Therapy was well tolerated with no treatment-related deaths.

CONCLUSIONS:

Mature results of the abbreviated Stanford V regimen in nonbulky early-stage HL are excellent and comparable to the results from other contemporary therapies.

PMID:
23136225
PMCID:
PMC3603439
DOI:
10.1093/annonc/mds542
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center